Investor Presentaiton
Our Results
Revenue growth: For the 6 months ended 30 June 2020, we continued to record revenue growth despite the
impact of COVID-19, with revenues increasing 3.0% y-o-y to RMB5,091m.
.
Our pharma packaging and orthopedics segments in particular recorded strong results, growing 22.1%
and 21.8% respectively to reach RMB764.5m and RMB830.6m in sales in 1H2020.
While sales from our Clinical Care segment in 1H2020 declined y-o-y due to COVID-19, we believe that
the impact is only temporary as COVID-19 continues to stabilize, and that our diversified product mix and
our scale will enable us to resume growth and further our market leadership going forward.
Our gross profit margins declined from 63.4% to 57.8% as a result of product mix changes due to COVID-
19.
Argon's results affected by COVID-19, but we remain positive on its outlook: Argon's performance in
1H2020 was affected as a result of the continued spread of COVID-19 across the world throughout the second
quarter of 2020.
In 1H2020, Argon recorded total sales RMB678.3m, representing a 3.8% decrease y-o-y. While sales
declined slightly when compared to 1H2019, Argon's net profit continued to record consistent growth.
Despite the short-term impact of COVID-19, we expect China to continue to be a major growth driver for
Argon in the coming years.
Continued increase in profitability: Our net income attributable to owners of the Company grew 3.5% in
1H2020, largely in line with revenue growth.
.
Despite the impact of the pandemic, we intend to continue fulfilling our commitment to provide consistent
returns to our shareholders. For 1H2020, we have announced a total dividend of 6.2 cents, representing a
5.1% increase to 1H2019.
WEGO威高
1View entire presentation